| AASLD

Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years

Read more about Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years

Faouzi Saliba, Christophe Duvoux, Sébastien Dharancy, Jérôme Dumortier, Yvon Calmus, Jean Gugenheim, Nassim Kamar, Ephrem Salamé, Martine Neau‐Cransac, Claire Vanlemmens, François Durand, Georges Pageaux, Vincent Leroy, Jean Hardwigsen, Hakam Gharbi, Cécile Masson, Malka Tindel, Filomena Conti – 21 October 2019 – The observational CERTITUDE study follows liver transplant patients who completed the SIMCER trial.

The Two Faces of Relaxin in Cancer: Antitumor or Protumor?

Read more about The Two Faces of Relaxin in Cancer: Antitumor or Protumor?

Sumera Rizvi, Gregory J. Gores – 20 October 2019

Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity

Read more about Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity

Toshihiro Sugiyama – 20 October 2019

Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Read more about Fatty Acid Synthase Inhibitor TVB‐2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Majid M. Syed‐Abdul, Elizabeth J. Parks, Ayman H. Gaballah, Kimberlee Bingham, Ghassan M. Hammoud, George Kemble, Douglas Buckley, William McCulloch, Camila Manrique-Acevedo – 20 October 2019

Reply:

Read more about Reply:

Yoshitaka Arase, Tatehiro Kagawa – 19 October 2019

Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers

Read more about Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers

Felix Stickel, Philipp Lutz, Stephan Buch, Hans Dieter Nischalke, Ines Silva, Vanessa Rausch, Janett Fischer, Karl Heinz Weiss, Daniel Gotthardt, Jonas Rosendahl, Astrid Marot, Mona Elamly, Marcin Krawczyk, Markus Casper, Frank Lammert, Thomas W. M. Buckley, Andrew McQuillin, Ulrich Spengler, Florian Eyer, Arndt Vogel, Silke Marhenke, Johann Felden, Henning Wege, Rohini Sharma, Stephen Atkinson, Andre Franke, Sophie Nehring, Vincent Moser, Clemens Schafmayer, Laurent Spahr, Carolin Lackner, Rudolf E. Stauber, Ali Canbay, Alexander Link, Luca Valenti, Jane I. Grove, Guruprasad P.

LiverLearning®: 2019 Webinar: The Diverse Presentation and Diagnosis of Liver Injury Due to Drugs or Herbal and Dietary Supplements

Read more about LiverLearning®: 2019 Webinar: The Diverse Presentation and Diagnosis of Liver Injury Due to Drugs or Herbal and Dietary Supplements

This webinar is targeted to AASLD Associate and Trainee members, as well as Junior Faculty. The goal is to provide an approach to the accurate diagnosis of Drug Induced Liver Injury (DILI), with special attention to considerations that may mask the diagnosis. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Paul (Skip) Hayashi Dr. Hayashi is currently Co-Chair of the Causality Committee for the Drug-Induced Liver Injury Network (DILIN) and Associate Professor at the University of North Carolina (UNC), Chapel Hill, NC.